Eli Lilly continues to dominate the obesity market with Zepbound and Orforglipron, leading JPMorgan to see it as a top pick ...

Novo Nordisk has rebounded strongly in 2025, backed by solid financials despite earlier setbacks and competitive risks. See ...

The trial’s results, expected by June 2025, could significantly impact the company’s position in the diabetes treatment ... favoring Wegovy over Zepbound, may affect Eli Lilly’s market dynamics.

The 30-stock Dow lost 44.14 points, or 0.10%, and ended at 42,171.66. The S&P 500 slipped 0.03% to close at 5,980.87, and the ...

They were designed to treat diabetes, then prescribed for weight loss, and now—as researchers are finding—they might hold the ...

Eli Lilly will ship the two highest doses of its popular weight-loss drug Zepbound to cash-paying customers on its website ...

Scholar Rock’s investigational spinal muscular atrophy drug helped patients taking Eli Lilly’s obesity blockbuster Zepbound ...

Eli Lilly's stock price has over-corrected following a downgrade in its outlook following the adjustment for acquisition ...

Starting July 7, 2025, the two highest doses of Zepbound will be available for a flat price of $499 per month, with shipments beginning in August. Eli Lilly announced that all approved single-dose ...

Under Lilly’s savings-card program for commercially insured people who lack coverage for Zepbound, a one-month prescription for Zepbound pens now costs a minimum of $650, up from $550 previously.

Novo Nordisk is making moves to retain its market share in the weight loss space after Eli Lilly's tirzepatide won a ...

While the results were an important proof point for so-called anti-myostatin drugs, Scholar Rock executives indicated the ...